Benzinga | Dec 13, 2021 09:26AM EST

Advanced Human Imaging Expands Presence Into Latin America With Nextmedicall Partnership; Terms Not Disclosed

Advanced Human Imaging Limited (ASX:AHI) (NASDAQ:AHI) ("AHI" or the "Company") is pleased to announce the signing of a binding term sheet with NEXTMEDICALL S.A.C ("Nextmedicall"), a Peruvian-based telemedicine company.

Nextmedicall offers reliable care from the comfort of a patient's home with teleconsultation for all medical specialties through the platforms extensive network of doctors and specialists. Pursuant to the binding term sheet, Nextmedicall will integrate the AHI MultiScan Software Development Kit into the Nextmedicall platform. The initial integration will allow access to AHI's proprietary BodyScan and FaceScan with the intention to add DermaScan, HemaScan and other offerings from AHI once released in 2022.

The integration will allow Nextmedicall users to track and ascertain dimensional-based risk assessments and vital signs prior to and during telehealth consultation. Nextmedicall will leverage the partnership to identify early onset chronic disease markers and chronic disease risk for early intervention and provision of care across Latin America.

Nextmedicall conducted due diligence of the AHI CompleteScan platform prior to signing the binding term sheet with AHI and is currently running a pilot program with Chilean Telecommunications provider Entel Chile.

"I am pleased to expand the AHI offering into Latin America with Nextmedicall. The scope of their medical team and offering is significant and it will help us deliver our solution to a large population in need of cost-effective care," said Vlado Bosanac, Chief Executive Officer of Advanced Human Imaging. "The Nextmedicall team has a deep understanding of the telecommunications industry and the need to deliver more value to patients of these services. Through this partnership, Nextmedicall wishes to triage patients into early intervention and care. This will reduce the need for episodic care, through early diagnosis and intervention that results in better health outcomes."

Nextmedicall will commence integration of the AHI technology into the Nextmedicall platform in a white-label solution within 120 days from the signing of the binding term sheet.